DSCAR01 / Hrain Biotech - LARVOL DELTA

As Fast As We Can: Rational Design of Rapid Chimeric Antigen Receptor T Cell Manufacturing (ASH 2023) - "Tumor cell-xenograft NOG mice models were confirmed the anti-tumor activity of DASH CD19 CAR-T cells in vivo...Cell viability, stemness of T cells, CAR expression, and removal of impurity were improved in the CAR-T product manufactured by this novel process. Based on the preclinical study results, an investigator-initiated trial (IIT) has launched to explore the safety, efficacy, pharmacokinetic/pharmacodynamics characteristics in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)."

CAR T-Cell Therapy • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • ANXA5 • CD19

Evaluation of CD70 Chimeric Antigen Receptor T (CAR-T) Cells As a Potential Treatment for Non-Hodgkin's Lymphoma: A Preclinical Study (ASH 2023) - " We successfully generated CD70 CAR-T cells based on a VHH nanobody (11C9) and CD19 CAR-T cells based on murine scFv (FMC63) following the exact manufacturing protocols used for phase I and phase II clinical trial products respectively... Our results indicate that CD70 CAR-T cell is potential treatment for NHL. We will conduct an investigation of single and dual CD70 CAR-T on treatment of lymphoma especially for CD19 negative NHL."

CAR T-Cell Therapy • IO biomarker • Preclinical • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Genito-urinary Cancer • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CD70 • TNFA

Preclinical study of DASH CAR-T cells manufactured in 48 hours (ESMO 2022) - "Strikingly, 4 out 5 mice treated with one million anti-CD19 DASH CAR-T cells survived beyond 60 days. In contrast, 1 or 2 out of 5 mice treated with one million or 5 million anti-CD19 CAR-T cells survived. Conclusions DASH CAR-T cells manufactured in two days expanded significantly better in vivo and more effective than conventional CAR-T cells. Clinical trials are planned to use DASH CAR-T platform to rapidly generate CAR-T cells to treat patients with ALL or r/r B-ALL."

CAR T-Cell Therapy • IO biomarker • Preclinical • Acute Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CCR7 • PTPRC

A Phase Ⅱ Clinical Trial of CD19 CAR-T Cell Infusion for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Hrain Biotechnology Co., Ltd.

CAR T-Cell Therapy • New P2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

MeCAR: Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma (clinicaltrials.gov) - P1/2; N=20; Recruiting; Sponsor: Xinqiao Hospital of Chongqing; Trial primary completion date: Dec 2017 ➔ Jun 2019

Clinical • Trial primary completion date